Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Sees Significant Decline in Short Interest

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the recipient of a large decrease in short interest during the month of September. As of September 15th, there was short interest totaling 84,256 shares, a decrease of 69.1% from the August 31st total of 272,812 shares. Based on an average trading volume of 172,085 shares, the days-to-cover ratio is presently 0.5 days. Currently, 1.3% of the company’s stock are sold short.

Creative Medical Technology Trading Down 1.9%

CELZ stock opened at $1.01 on Tuesday. The stock’s 50 day simple moving average is $1.01 and its 200 day simple moving average is $1.61. Creative Medical Technology has a 12-month low of $0.62 and a 12-month high of $6.25. The firm has a market cap of $6.66 million, a P/E ratio of -0.49 and a beta of 2.04.

Creative Medical Technology (NASDAQ:CELZ) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). On average, research analysts forecast that Creative Medical Technology will post -1.18 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Weiss Ratings downgraded shares of Creative Medical Technology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Wall Street Zen upgraded Creative Medical Technology from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Finally, Roth Capital reiterated a “buy” rating on shares of Creative Medical Technology in a research note on Thursday, August 20th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold”.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc is a biotechnology company focused on developing regenerative medicine and cell-based therapies. The company’s research programs are aimed at conditions involving inflammation, autoimmune dysfunction, tissue damage and sexual health.

Its pipeline has included ImmCelz, an immunomodulatory cell-therapy platform, as well as CaverStem for erectile dysfunction, FemCelz for female sexual health, KneeCelz for knee-related conditions and StemSpine for spinal disorders.